Anti-Infective Peptides to Enhance the Host Innate Response: Design, Development and Delivery

Research output: Contribution to journalArticleResearchpeer-review

Abstract

BACKGROUND: Inducible Nitric Oxide Synthase (iNOS or NOS2) produces Nitric Oxide (NO) and related reactive nitrogen species, which are critical effectors of the host innate response and play key roles in the intracellular killing of bacterial and parasitic pathogens. The SPRY domain- containing SOCS box proteins SPSB1 and SPSB2 are key physiological regulators of this important enzyme. Disrupting the endogenous SPSB-iNOS interaction should prolong the intracellular lifetime of iNOS and enhance the production of NO, and therefore be beneficial in treating chronic and persistent infections such as tuberculosis. By using structure-based design, potent peptide inhibitors of this interaction have been developed. 

CONCLUSION: Inhibitors of the SPSB-iNOS interaction have therapeutic potential as a novel class of anti-infective agents. Various strategies are being pursued to target these peptide inhibitors to macrophages and deliver them to the cytoplasm of these cells. It will then be possible to assess the efficacy of such inhibitors in boosting the capacity of macrophages to destroy infectious pathogens.

Original languageEnglish
Pages (from-to)1101-1107
Number of pages7
JournalProtein and Peptide Letters
Volume25
Issue number12
DOIs
Publication statusPublished - 2018

Keywords

  • delivery
  • macrophage
  • Nitric oxide
  • pathogen
  • peptide
  • protein-protein interaction
  • structure
  • targeting.

Cite this

@article{d7db0410af2a4276bd91f26e42282a98,
title = "Anti-Infective Peptides to Enhance the Host Innate Response: Design, Development and Delivery",
abstract = "BACKGROUND: Inducible Nitric Oxide Synthase (iNOS or NOS2) produces Nitric Oxide (NO) and related reactive nitrogen species, which are critical effectors of the host innate response and play key roles in the intracellular killing of bacterial and parasitic pathogens. The SPRY domain- containing SOCS box proteins SPSB1 and SPSB2 are key physiological regulators of this important enzyme. Disrupting the endogenous SPSB-iNOS interaction should prolong the intracellular lifetime of iNOS and enhance the production of NO, and therefore be beneficial in treating chronic and persistent infections such as tuberculosis. By using structure-based design, potent peptide inhibitors of this interaction have been developed. CONCLUSION: Inhibitors of the SPSB-iNOS interaction have therapeutic potential as a novel class of anti-infective agents. Various strategies are being pursued to target these peptide inhibitors to macrophages and deliver them to the cytoplasm of these cells. It will then be possible to assess the efficacy of such inhibitors in boosting the capacity of macrophages to destroy infectious pathogens.",
keywords = "delivery, macrophage, Nitric oxide, pathogen, peptide, protein-protein interaction, structure, targeting.",
author = "Norton, {Raymond S.}",
year = "2018",
doi = "10.2174/0929866525666181101104945",
language = "English",
volume = "25",
pages = "1101--1107",
journal = "Protein and Peptide Letters",
issn = "0929-8665",
publisher = "Bentham Science Publishers",
number = "12",

}

Anti-Infective Peptides to Enhance the Host Innate Response : Design, Development and Delivery. / Norton, Raymond S.

In: Protein and Peptide Letters, Vol. 25, No. 12, 2018, p. 1101-1107.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Anti-Infective Peptides to Enhance the Host Innate Response

T2 - Design, Development and Delivery

AU - Norton, Raymond S.

PY - 2018

Y1 - 2018

N2 - BACKGROUND: Inducible Nitric Oxide Synthase (iNOS or NOS2) produces Nitric Oxide (NO) and related reactive nitrogen species, which are critical effectors of the host innate response and play key roles in the intracellular killing of bacterial and parasitic pathogens. The SPRY domain- containing SOCS box proteins SPSB1 and SPSB2 are key physiological regulators of this important enzyme. Disrupting the endogenous SPSB-iNOS interaction should prolong the intracellular lifetime of iNOS and enhance the production of NO, and therefore be beneficial in treating chronic and persistent infections such as tuberculosis. By using structure-based design, potent peptide inhibitors of this interaction have been developed. CONCLUSION: Inhibitors of the SPSB-iNOS interaction have therapeutic potential as a novel class of anti-infective agents. Various strategies are being pursued to target these peptide inhibitors to macrophages and deliver them to the cytoplasm of these cells. It will then be possible to assess the efficacy of such inhibitors in boosting the capacity of macrophages to destroy infectious pathogens.

AB - BACKGROUND: Inducible Nitric Oxide Synthase (iNOS or NOS2) produces Nitric Oxide (NO) and related reactive nitrogen species, which are critical effectors of the host innate response and play key roles in the intracellular killing of bacterial and parasitic pathogens. The SPRY domain- containing SOCS box proteins SPSB1 and SPSB2 are key physiological regulators of this important enzyme. Disrupting the endogenous SPSB-iNOS interaction should prolong the intracellular lifetime of iNOS and enhance the production of NO, and therefore be beneficial in treating chronic and persistent infections such as tuberculosis. By using structure-based design, potent peptide inhibitors of this interaction have been developed. CONCLUSION: Inhibitors of the SPSB-iNOS interaction have therapeutic potential as a novel class of anti-infective agents. Various strategies are being pursued to target these peptide inhibitors to macrophages and deliver them to the cytoplasm of these cells. It will then be possible to assess the efficacy of such inhibitors in boosting the capacity of macrophages to destroy infectious pathogens.

KW - delivery

KW - macrophage

KW - Nitric oxide

KW - pathogen

KW - peptide

KW - protein-protein interaction

KW - structure

KW - targeting.

UR - http://www.scopus.com/inward/record.url?scp=85060952044&partnerID=8YFLogxK

U2 - 10.2174/0929866525666181101104945

DO - 10.2174/0929866525666181101104945

M3 - Article

VL - 25

SP - 1101

EP - 1107

JO - Protein and Peptide Letters

JF - Protein and Peptide Letters

SN - 0929-8665

IS - 12

ER -